Correcting and Replacing Corporate Profile for NeXstar Pharmaceuticals, dated 10/17/97.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: 10/17/97
Company Name: NeXstar Pharmaceuticals
Address: 2860 Wilderness Pl.
Boulder, CO 80301
Main Telephone
Number: 303/444-5893
Internet Home
Page Address
(URL)/email: www.nexstar.com
ir@nexstar.com or corpcom@nexstar.com
Chief Executive
Officer: Patrick J. Mahaffy
Investor Relations
Contact: Michael Hart, CFO
Business number: 303/546-7613
Public Relations
Contact: Katy S. Doherty
Business number: 303/546-7889
Trading Symbol/
Exchange: NXTR:NASDAQ
Industry: Pharmaceutical/Biotech
Company description: NeXstar Pharmaceuticals Inc. is a fully integrated biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious oncological, immunological, hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. and infectious diseases. NeXstar Pharmaceuticals employs a broad range of proprietary technologies, including a unique liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. drug delivery technology and powerful proprietary combinatorial chemistry technologies called the SELEX SELEX Systematic Evolution of Ligands By Exponential Enrichment SELEX Segmented Large X (baryon spectrometer) process and the Parallel SELEX process. These technologies have produced two approved drugs and several drug candidates that are in clinical or preclinical development. Currently, NeXstar Pharmaceuticals markets AmBisome, an antifungal agent, and DaunoXome, an anticancer drug, which had combined first quarter 1997 and fiscal year 1996 revenues of $20 million and $80.2 million, respectively, compared to first quarter 1996 and fiscal year 1995 revenues of $17.5 million and $57.8 million, respectively. AmBisome has been approved for sale by regulatory authorities in 29 countries, including 12 countries in which it has been approved as a primary therapy for some forms of fungal infection. In August 1997, the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) approved AmBisome in the United States as a primary therapy for presumed fungal infections in febrile febrile /feb·rile/ (feb´ril) pertaining to or characterized by fever. feb·rile adj. Of, relating to, or characterized by fever; feverish. neutropenic (low white blood cell count white blood cell count, n a diagnostic clinical laboratory test to determine the number and types of leukocytes present in a measured sample of blood. Overall the normal number of leukocytes ranges from 5000 to 10,000/mm3. ) patients (known as fever of unknown origin Fever of Unknown Origin Definition Fever of unknown origin (FUO) refers to the presence of a documented fever for a specified time, for which a cause has not been found after a basic medical evaluation. , or FUO FUO fever of unknown origin. FUO abbr. fever of unknown origin FUO fever of unknown origin. FUO Fever of unknown origin, see there ), as a primary therapy for visceral leishmaniasis, and as a secondary treatment for fungal infections that do not respond to amphotericin B treatment. CONTACT: NeXstar Pharmaceuticals Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion